March 10, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announced on February 16, 2017, an interim dividend of 25.70 US cents per Ordinary Share payable on April 25, 2017, to shareholders on the register of members at the close of business on March 10, 2017.
Holders of Ordinary Shares are notified that, in order to receive UK sourced dividends via the Company’s Income Access Share arrangements (“IAS Arrangements”), they need to have submitted a valid IAS Arrangements election form to the Company’s Registrar, Equiniti, by no later than 5pm (GMT) on March 24, 2017.
Holders of Ordinary Shares are advised that:
Internet links to the newly formatted IAS Arrangements election forms can be found at: http://investors.shire.com/shareholder-information/shareholder-forms.aspx
For further information concerning the IAS Arrangements, please contact Equiniti (+44 (0) 121 415 7593). If you are in any doubt as to what action to take, please consult your tax advisor immediately.
Senior Assistant Company Secretary
|Ian Karpfirstname.lastname@example.org||+1 781 482 9018|
|Robert Coatesemail@example.com||+44 1256 894874|
|Lisa Adlerfirstname.lastname@example.org||+1 617 588 8607|
|Debbi Fordemail@example.com||+1 617 949 9083|
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.